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Since the early 1980s there has been concern about the high incidence 
of upper respiratory tract infections (URTIs) among athletes during 
periods of intensive exercise training and exhaustive endurance 
events.1,2 This results in interrupted training schedules and impaired 
performance in competitive events. Exercise immunologists have 
sought methods to identify the cause of these symptoms, which have 
now been extended to include the lower respiratory tract.3
Of post-exercise respiratory tract symptoms (RTS), 30 - 40% of 
cases are the result of infection, a further 30% are due to inflammation, 
and the final 30% are from unknown causes.2,4-6 Numerous theories 
have been proposed to account for the occurrence of non-infective 
post-exercise RTS, including the development of hyper-reactive 
airways,7 runaway inflammatory responses,8 reactivation of latent 
viral infection6 and allergic reactions.3,9
It has been documented that athletes experience higher rates 
of allergic disease than the general population10 and that the 
cited incidence of allergy among Olympic athletes is increasing.11 
Exercise-induced symptoms of infection of the respiratory tract can 
mimic an allergic reaction,3 and exercise induces a TH2-dominant 
immunological shift;2 therefore, it may up-regulate an allergic 
response in those already sensitised.9 Increased exposure of athletes 
to irritants and allergens may contribute to this.3,11
Although the skin prick test (SPT) is generally accepted as the 
standard method for detecting IgE-related allergic sensitisation,12 
its limitations include a lowered response in the elderly, greater 
difficulty in grading the response in dark-skinned persons, its contra-
indication in pregnancy, the quality and selection of allergens, and 
the theoretical risk of anaphylaxis.13
Specific IgE antibody testing is accepted as an alternative to the 
SPT.12 Combination tests such as the Phadiatop assay (Pharmacia 
& Upjohn Diagnostics, Uppsala, Sweden) simultaneously test for 
IgE to a mixture of allergens causing common inhalant allergies. 
Allergens included in the Phadiatop assay are Artemisia, dust mites 
(Dermatophagoides pteronyssinus and D. farinae), mixed moulds 
(Penicillium, Cladosporium, Aspergillus and Alternaria), pet dander 
(cat and dog), mixed grasses (Parietaria, Lolium, Phleum and 
Cynodon), and mixed trees (Acer, Betula, Olea, Salix, Pinus, Ulmus, 
Quercus, Eucalyptus, Acacia and Melaleuca).14 This assay has been 
found satisfactory for the diagnosis of IgE allergic sensitisation in the 
general population, with a sensitivity of 70.8% and a specificity of 
90.7% compared with the SPT.12 
Our objectives were to: (i) investigate the validity of the Phadiatop 
test as a predictor of allergy-associated RTS in athletes competing in 
a 3-day 95 km trail run, (ii) document the incidence of RTS before, 
during and after the event, and (iii) relate these incidences to the 
concentrations of serum IgE, leucocyte sub-classes and Phadiatop 
status of the athletes throughout and after the event.
Methods
This longitudinal study was part of a larger study examining 
physiological responses during the Three Cranes Challenge (a 3-day 
95 km trail run) in Karkloof, KwaZulu-Natal on 25 - 27 February 
2011. Local institutional ethical approval was obtained, and a sample 
of 22 volunteers signed informed consent forms.
After routine baseline testing on the afternoon before the race, 
venous blood samples were collected at a total of 8 time points, before 
and after each day’s stage (S1pre, S1post, S2pre, S2post, S3pre and S3post), 24 
hours post-race (24PR) and 72 hours post-race (72PR). RTS data 
were collected over a 31-day period, from 14 days prior to the race 
until the 14th day after the race. Of the 22 subjects, 16 completed the 
race and complied with all the study requirements. Two subjects were 
excluded as a result of failure to complete the race, and a further 4 did 
not complete post-race testing.
Athletes were asked to record the daily incidence and severity 
of RTS before, during and after the race using a graded 1 - 3-point 
scoring system. Symptoms monitored included cough, runny nose, 
sneezing, blocked nose, sore throat, headache, fever, tight chest and 
itchy eyes. A total RTS index score was determined using the sum of 
severity scores and the length of time that the symptom(s) persisted.
To determine which subjects qualified for post-exercise RTS, 
any subject presenting with a single RTS lasting <2 days or any 
nonspecific symptom (e.g. headache, itchy eyes) not accompanied 
by RTS lasting >1 day, was excluded. A peak post-stage or post-race 
serum IgE (sIgE) concentration below the clinically significant range 
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development of post-exercise RTS of allergic origin in trail runners.
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(100 IU/ml) excluded the possibility of the RTS being of allergic 
origin.
Full blood counts, pre-race Phadiatop status and sIgE 
concentrations were determined by Ampath Laboratories, Howick, 
KwaZulu-Natal, using an automated UniCAP system. In the 
Phadiatop assay, concentrations >0.35 IU/ml represented a positive 
response, irrespective of range.14
Exercise-induced changes in plasma volume (PV) over this 3-day 
event were determined from pre- and post-exercise haematocrit 
and haemoglobin concentrations.15 Post-exercise sIgE levels and 
concentration-dependent leucocyte counts were adjusted for 
percentage exercise-induced change in PV.
After confirmation of the absence of normality of the data, 
they were logarithmically transformed. A generalised linear model 
was applied to the median (range) sIgE and differential leucocyte 
concentration data from multiple subjects over multiple time points 
and between Phadiatop-positive and negative groups. The Mann-
Whitney U-test was used to compare the RTS data pre- and post-
race and between Phadiatop-positive and negative groups. Data are 
presented as the median (interquartile range (IQR)) in box-and-
whisker plots in Figs 1 and 2. Significance was set at p=0.05.
Results
Of the 16 subjects (12 women, 4 men; age 25 - 50 years), 9 were 
Phadiatop-positive and 7 were Phadiatop-negative. The median and 
range of body mass index (23.8, 18.7 - 27.7 v. 20.9, 19.7 - 25.3) and 
percentage body fat (20.9%, 15.7 - 29.3% v. 23.7%, 17.2 - 30.6%) did 
not differ significantly between Phadiatop-positive and negative 
groups. Baseline testing of vital signs was within the normal range, 
and subjects did not present with evidence of medical conditions that 
could have placed their health at risk. Table 1 presents the results of 
the Phadiatop assay and peak sIgE concentrations.
The criteria for post-race RTS were met by 12 (75%) subjects, of 
whom 7 (58%) were Phadiatop-positive and 5 (42%) were Phadiatop-
negative. The median (IQR) pre- and post-race RTS index scores of 
the Phadiatop groups did not differ significantly (p>0.05) (Fig. 1).
Fig. 2 presents the median (IQR) sIgE concentrations of the 
subjects (adjusted for PV). There was a non-significant (p=0.37) 
rise in the sIgE concentrations of the entire group over the course 
of testing, with highest concentrations recorded in 75% of subjects 
at the 24PR time period. There was a highly significant (p<0.001) 
difference between the sIgE concentrations of the Phadiatop-positive 
and negative groups.
Concentrations of sIgE reached clinical significance (peak sIgE 
>100 IU/ml) in 5 (42%) of the 12 RTS-positive subjects (4 Phadiatop-
positive and RTS-positive subjects and 1 Phadiatop-negative and 
RTS-positive subject).
There was no significant exercise-induced elevation in PV-adjusted 
concentrations of either basophils or eosinophils over time (p>0.05), 
and the difference between Phadiatop-positive and negative groups 
in terms of eosinophil or basophil response to 3 days of exercise was 
not significant (p>0.05).
Discussion
The incidence of post-exercise RTS in endurance runners in this 
study (n=12, 75%) was higher than that in most other reported 
studies,1-3 possibly owing to the inclusion of subjects with a prior 
history of allergy; in most previous studies, allergy was seen as a 
confounding factor in determining the incidence of URTI and was 
therefore excluded.
Interestingly, in this field trial, subjects with systemic evidence of 
RTS associated with an allergic reaction accounted for 42% (n=5) 
of the 12 cases with post-exercise RTS. However, as seen by the 
lack of significance between post-race RTS incidence in Phadiatop-
positive and negative groups (Fig. 1), the incidence of post-race RTS 
symptoms was not defined by the Phadiatop test.
Our primary finding was that, of the 7 Phadiatop-positive subjects 
who developed post-race RTS, only 4 (58%) displayed clinically 
elevated sIgE concentrations above the cut-off point for allergy (sIgE 
>100 IU/ml). The mildly elevated eosinophil concentrations often 
seen in allergic responses13 were not evident in the Phadiatop-positive 
group (p>0.05).
Although specific sIgE antibody testing (SPT) provides evidence of 
sensitisation to an allergen, an allergic disease response only develops 
once the individual is exposed to that particular allergen; therefore, 
although the Phadiatop test may provide satisfactory accuracy in 
identifying predisposition to allergic responsiveness to airborne 
allergens, on its own it may not predict the development of allergic 
Table 1. Phadiatop assay results and peak race-induced sIgE concentrations of the 16 subjects
Phadiatop-positive
(n=9)
Phadiatop-negative
(n=7)
Subject
Phadiatop result* 
(sIgE conc.) (IU/ml)
Peak sIgE conc. 
(IU/ml)† (time-point) Subject
Phadiatop result* 
(sIgE conc.) (IU/ml)
Peak sIgE conc. 
(IU/ml)† (time-point)
1 8.51 85.64 (24PR) 5 0.13 23.64 (24PR)
2 75.80 227.14 (24PR) 6 0.17 19.46 (72PR)
3 7.55 54.38 (24PR) 10 0.12 55.44 (24PR)
4 0.41 56.32 (24PR) 12 0.28 33.58 (24PR)
7 7.19 445.74 (24PR) 14 0.12 11.30 (24PR)
8 3.42 240.48 (72PR) 15 0.14 140.82 (24PR)
9 0.50 76.13 (24PR) 16 0.11 66.79 (24PR)
11 9.49 63.14 (24PR)
13 41.30 274.0 (S1pre)
Median 7.55‡ 85.64‡ Median 0.13 33.58
*sIgE reference range: Phadiatop 0.00 - 0.35 IU/ml.
†Reference range: total sIgE 0.00 - 100 IU/ml.
‡p<0.001 v. Phadiatop-negative group; generalised linear model.
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disease in trail runners. Owing to the fixed selection of allergens, it 
is theoretically possible to miss subjects who are sensitised to less 
common inhalant allergens (such as local flora or fauna), as was the 
case in one of our subjects.
The predictive validity of the Phadiatop assay for the incidence 
of exercise-induced RTS of allergic origin in the trail runners must 
therefore be questioned.
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Fig. 1. Median (IQR) pre- (left) and post-race (right) total RTS index scores 
of Phadiatop-positive* (n=9) and negative (n=7) groups. (*sIgE concentra-
tion >0.35 IU/ml in Phadiatop assay)
Fig. 2. Median (IQR) of absolute sIgE* concentrations† of Phadiatop-positive 
and negative groups, at 8 stages during and after a 3-day 95 km trail run. 
(*Adjusted for plasma volume; †Reference range 0 - 100 IU/ml)
